India’s growing nutraceutical market is facing increased scrutiny after a review found that 60 advertisements for health and wellness supplements failed to meet advertising standards. The findings have raised concerns about products promising rapid weight loss, younger-looking skin and even the reversal of medical conditions without adequate scientific evidence.
The Advertising Standards Council of India (ASCI) examined 61 advertisements identified between July and September 2026. Investigations into 60 advertisements had been completed when the findings were released on October 28, and all 60 were found to violate the organisation’s advertising code. One case remained under review.
The findings come as the Food Safety and Standards Authority of India (FSSAI) strengthens its focus on supplement labelling, particularly for products containing botanical ingredients.
Weight-loss and disease-related promises under scrutiny
The advertisements reviewed covered several areas, including weight management, skincare, anti-ageing and respiratory health. Some made specific promises about how quickly consumers could see results.
Examples included claims that a product could help users lose six kilograms in 60 days, make skin appear seven years younger or provide 300% stronger protection against ultraviolet damage.
Other advertisements suggested that supplements could reverse asthma or polycystic ovarian disease (PCOD). Such claims are particularly concerning because they can make consumers believe that a food supplement can replace medical treatment.
Of the 60 advertisements found to violate the code, 29 advertisers did not contest the objections. The remaining 31 challenged the findings but failed to provide sufficient evidence to substantiate their claims.
The review also raised concerns about advertisements suggesting that certain products could improve lung health or reverse the effects of smoking and pollution.
Importantly, an advertising-code violation does not automatically establish that every product involved is unsafe. The central issue is whether the specific benefits promised in the advertisements were supported by adequate evidence.
Why ingredient research may not prove a product's effectiveness
A major concern identified in the review was the use of research on individual ingredients to support claims about complete commercial products.
A nutrient or plant extract may have been studied in a controlled research setting. However, those findings cannot automatically be applied to every supplement containing that ingredient.
The final product may differ in its formulation, concentration, dosage and combination of ingredients. These factors can influence how the body responds to it.
The review also highlighted exaggerated comparisons, rapid-result promises and before-and-after images that could create unrealistic expectations.
Scientific terminology and references to research may make an advertisement appear credible, but consumers need evidence that directly supports the advertised product and its particular claims.
What India's nutraceutical regulations require
In India, nutraceuticals and health supplements are regulated as food products rather than medicines. Their composition, permitted ingredients, usage levels and labelling are governed by the Food Safety and Standards Regulations, 2016.
These products may provide nutritional or physiological benefits, but they cannot generally be presented as treatments or cures for diseases.
This distinction is important because a supplement marketed for general wellness is not equivalent to a medicine prescribed to manage a medical condition. Claims suggesting that a product can treat, cure, mitigate or prevent a disease are restricted unless specifically permitted under the applicable regulatory framework.
The Food Safety and Standards (Advertising and Claims) Regulations, 2018, also require health and nutritional claims to meet prescribed conditions and have appropriate scientific support. Advertisers cannot rely on limited ingredient-level research to promise benefits that have not been demonstrated for the finished product.
FSSAI strengthens rules on botanical ingredients
On October 15, 2026, FSSAI issued an advisory reminding manufacturers and other food businesses about mandatory labelling requirements and warnings for plant-based and botanical ingredients used in nutraceuticals and specialised food products.
The requirements include identifying the plant part used and providing applicable cautionary statements or warnings for relevant ingredients.
These details matter because herbal and botanical substances can have physiological effects, possible contraindications and interactions with medicines. Describing a product as natural does not remove the need for appropriate safety information.
Non-compliance can lead to regulatory action under the Food Safety and Standards Act, 2006, including penalties and other measures where applicable.
Consumer protection laws also cover misleading advertisements
The Consumer Protection Act, 2019, provides another mechanism for addressing false or misleading advertising. The Central Consumer Protection Authority can take action against advertisements that deceive consumers or make unsupported promises.
The 2022 guidelines on misleading advertisements and endorsements require promotional claims to be truthful and properly supported. Penalties can reach Rs 10 lakh for a first contravention and Rs 50 lakh for subsequent violations, subject to the applicable provisions.
ASCI operates as an advertising self-regulatory organisation. It reviews advertisements under its code and can seek changes or withdrawal, while government authorities exercise powers under their respective laws.
What consumers should remember
The latest findings highlight the importance of evaluating health products carefully. Consumers should read labels, check ingredient and dosage information, pay attention to warnings and remain cautious about advertisements promising dramatic or guaranteed results.
People with existing medical conditions or those taking prescribed medicines should seek advice from a qualified healthcare professional before using supplements. Nutraceuticals should not be treated as substitutes for prescribed treatment.
India already has regulations covering supplement composition, labelling, advertising and consumer protection. The challenge now is ensuring that these rules are followed consistently and that health-related marketing remains aligned with credible scientific evidence.
The ASCI review sends a clear message to the industry: claims about health benefits must be supported by evidence, and promotional promises should not go beyond what research can establish.
